Aigen Investment Management LP Increases Stake in Guardant Health, Inc. (NASDAQ:GH)

Aigen Investment Management LP boosted its stake in Guardant Health, Inc. (NASDAQ:GH) by 23.9% in the third quarter, Holdings Channel.com reports. The firm owned 19,103 shares of the company’s stock after acquiring an additional 3,683 shares during the quarter. Aigen Investment Management LP’s holdings in Guardant Health were worth $438,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JNBA Financial Advisors acquired a new position in shares of Guardant Health in the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC purchased a new position in Guardant Health in the third quarter valued at approximately $34,000. Quarry LP acquired a new position in Guardant Health during the second quarter valued at approximately $44,000. Canton Hathaway LLC purchased a new stake in Guardant Health during the second quarter worth approximately $59,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Guardant Health in the second quarter worth $71,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Buying and Selling

In other Guardant Health news, Director Meghan V. Joyce sold 2,896 shares of Guardant Health stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now directly owns 7,648 shares in the company, valued at $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 5.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on GH shares. Citigroup lifted their target price on shares of Guardant Health from $40.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, August 8th. The Goldman Sachs Group upped their target price on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. BTIG Research raised their target price on Guardant Health from $45.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. TD Cowen boosted their price target on Guardant Health from $41.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Finally, Leerink Partners lowered their price objective on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.60.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $30.21 on Friday. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.85 and a current ratio of 6.22. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $37.04. The firm’s 50-day simple moving average is $23.57 and its 200-day simple moving average is $26.33. The firm has a market cap of $3.73 billion, a PE ratio of -7.13 and a beta of 1.11.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The firm had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.73) EPS. Equities analysts forecast that Guardant Health, Inc. will post -3.38 earnings per share for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.